No observed dose-limiting toxicity to date when SQ3370 is administered at doses up to 12 times higher than conventional doxorubicin; dose escalation is ongoing

SAN FRANCISCO, CA, May 31, 2022 – Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) platform, will present interim data from its Phase 1 clinical study of SQ3370 in advanced solid tumors, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago, IL, on June 3-7, 2022.

Presentation details:

• Abstract Title: Interim Phase 1 results for SQ3370 in advanced solid tumors
• Abstract Number: 3085
• Poster Number: 77
• Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
• Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT

Key highlights include:

• 26 patients received treatment with SQ3370 and as of the data cutoff date, 21 patients were evaluable
• 77% of patients had metastases with a median number of 2 metastatic sites (1-5); most frequently lung (50%) and more than 50% being previously treated with doxorubicin
• Escalating doses of SQP33 protodrug ranging from 0.38x to 12x the molar equivalent of conventional doxorubicin per cycle along with a dose of 10 or 20 mL of SQL70 were administered
• SQ3370 was well tolerated with 62% of patients receiving more than 500 mg/m 2 cumulative doxorubicin equivalents given as SQP33
• The most common treatment emergent adverse events reported were nausea, fatigue, anemia, and constipation
• At a median follow-up of 9.2 weeks, of the 21 evaluable patients, 71% had stable disease, with a median duration of 80 days
• Dose escalation continues as the maximum tolerable dose has not yet been reached
• SQ3370 demonstrates proof of concept for the CAPAC platform

‍